OS Therapies Files 8-K for March 31, 2025
Ticker: OSTX · Form: 8-K · Filed: Apr 2, 2025 · CIK: 1795091
| Field | Detail |
|---|---|
| Company | Os Therapies Inc (OSTX) |
| Form Type | 8-K |
| Filed Date | Apr 2, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, financial-statements, exhibits
TL;DR
OS Therapies filed an 8-K on 4/2 for 3/31, mostly financial docs.
AI Summary
OS Therapies Inc. filed an 8-K on April 2, 2025, reporting events as of March 31, 2025. The filing primarily concerns financial statements and exhibits, with no specific material events detailed in the provided text.
Why It Matters
This 8-K filing indicates that OS Therapies Inc. is providing updated financial information and exhibits to the SEC, which is standard for public companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any unusual or high-risk events.
Key Players & Entities
- OS Therapies Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- 410-297-7793 (phone_number) — Registrant's telephone number
- March 31, 2025 (date) — Date of earliest event reported
- April 2, 2025 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing for OS Therapies Inc.?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of March 31, 2025.
When was the earliest event reported in this filing?
The earliest event reported in this filing was as of March 31, 2025.
What is the exact name of the registrant?
The exact name of the registrant is OS Therapies Incorporated.
In which state was OS Therapies Inc. incorporated?
OS Therapies Inc. was incorporated in Delaware.
What is the principal executive office address for OS Therapies Inc.?
The principal executive office address is 115 Pullman Crossing Road, Suite 103, Grasonville, Maryland 21638.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 2, 2025 regarding OS Therapies Inc (OSTX).